Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations

BACKGROUND: The addition of bevacizumab or pembrolizumab to pemetrexed-platinum chemotherapy has produced significant clinical benefits to patients with untreated, advanced non-squamous non-small cell lung cancer (NSCLC) lacking targetable genetic aberrations. However, the direct comparison between...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jiatao, Liu, Chang, Long, Qianqian, Wu, Xianghua, Wang, Huijie, Yu, Hui, Sun, Si, Zhang, Yao, Lin, Ying, Zhao, Xinmin, Wang, Jialei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511673/
https://www.ncbi.nlm.nih.gov/pubmed/34660317
http://dx.doi.org/10.3389/fonc.2021.752545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511673/
https://www.ncbi.nlm.nih.gov/pubmed/34660317
http://dx.doi.org/10.3389/fonc.2021.752545

Ejemplares similares